Published in final edited form as:

J Pain. 2017 December ; 18(12): 1542–1550. doi:10.1016/j.jpain.2017.08.004.

Improvement in the Spatial Distribution of Pain, Somatic Symptoms, and Depression Following a Weight-Loss Intervention

Andrew Schrepf, PhD¹, Steven E. Harte, PhD¹, Nicole Miller, RD, MPH², Christine Fowler, MS, RD², Catherine Nay, MEd, RD², David A. Williams, PhD¹, Daniel J. Clauw, MD¹, and Amy Rothberg, MD^{2,3}

¹Chronic Pain and Fatigue Research Center, Department of Anesthesiology, University of Michigan, Ann Arbor, MI

²Department of Internal Medicine, University of Michigan, Ann Arbor, MI

³School of Public Health, University of Michigan, Ann Arbor, MI

Abstract

Weight loss is known to improve pain localized to weight bearing joints but it is not known how weight loss affects the spatial distribution of pain and associated somatic symptoms like fatigue. We sought to determine if weight loss using a low calorie diet improves pain, affect, and somatic symptoms commonly associated with chronic pain conditions in an observational study. We also documented changes in inflammatory markers in serum before and after weight loss. Participants were 123 obese individuals undergoing a 12–16 week calorie restriction weight loss intervention. The spatial distribution of pain, symptom severity (e.g., fatigue, sleep difficulties), depression, and total fibromyalgia scale scores were measured before and after weight loss. Pain ($p = .022$), symptom severity ($p = .004$), depression ($p < .001$), and fibromyalgia scores ($p = .004$) improved following weight loss; men showed greater improvement than women on somatic symptoms and fibromyalgia scores (both $p < .01$). Those who lost at least 10% of body weight showed greater improvement than those who lost less than 10%. Levels of the regulatory cytokine Interleukin-10 increased following the intervention ($p = .002$). Weight loss may improve diffuse pain and comorbid symptoms commonly seen in chronic pain participants.

Keywords

obesity; inflammation; widespread pain; weight loss

Corresponding Author: Andrew Schrepf, PhD, University of Michigan, Chronic Pain and Fatigue Research Center, Department of Anesthesiology, 24 Frank Lloyd Wright Drive, PO Box 385, Lobby M, Ann Arbor, MI 48106. Phone: (734)-998-7045; FAX: (734)-998-6900, aschrepf@med.umich.edu.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Disclosures: The authors declare no conflicts of interest related to this work to disclose.

Introduction

According to 2011–2012 estimates, approximately 35% of adult Americans are obese.²⁷ Compared to their non-obese counterparts, a larger proportion of these obese individuals also suffer from pain, fatigue, cognitive difficulties, depression and non-refreshing sleep.^{2, 20} A number of explanations have been proposed to explain the link between pain and obesity. Many studies have focused on the mechanical load in weight-bearing joints. For instance, a recent investigation determined that significant weight loss following bariatric surgery was associated with a substantial reduction in knee and hip pain.²¹ Meta-analyses have also determined that obesity is strongly associated with low back pain.³⁶ Pain in obesity is not limited to weight-bearing joints however and reduced physical and mental well-being also play a large role in the reduced QOL associated with obesity, even in individuals without obesity-linked chronic conditions.¹⁸ The co-occurrence of all these symptoms suggests that systemic neurobiological and psychological mechanisms may contribute to their expression.^{20, 28} Understanding how the spatial distribution of pain and symptoms like fatigue are affected by weight loss may help develop more rational approaches to treatments for obese individuals with chronic pain.

A large number of neuroimaging studies have investigated abnormalities in pain-processing networks in individuals with high levels of widespread pain and associated clusters of systemic symptoms suggesting the potential of a common mechanism.³⁰ In addition, studies of single nucleotide polymorphisms (SNPs) affecting both mood and neurotransmission suggest commonalities between widespread pain and these systemic symptom clusters.²² Finally drugs that primarily modulate central neurotransmission have been found effective in treating widespread pain as well as having benefit for associated symptomatology.¹⁵ The underlying propensity to experience more widespread pain and a larger number of somatic symptoms has been shown to relate to important outcomes in both complex chronic pain conditions without obvious organic pathology and in patients with clear signs of peripheral nociceptive input.⁷ As examples, surrogate measures of this spectrum, such as the American College of Rheumatology (ACR) survey criteria for fibromyalgia, have proven effective at identifying patients at risk for persistent pain and analgesic non-responsiveness following joint replacement and hysterectomy.^{3, 17}

The symptom cluster containing sleep difficulties, pain, anxiety, depression, and low energy/fatigue (SPADE) has been described as a common symptomatic pentad that confers added impairment, treatment complications, and undermines health and functioning when present in the general population.¹⁰ This symptom cluster is similar to that of cytokine-induced sickness behavior studied in animal models⁹ and more recently has been documented in human clinical populations.¹⁶ One possibility is that pro-inflammatory modulation of CNS processes play a role in the expression of these symptoms.¹¹ Obesity is strongly related to plasma/serum levels of pro-inflammatory cytokines.⁶ Preclinical models demonstrate that obesity leads to the accumulation of macrophages in adipose tissue⁴¹ and a switch in sentinel immune cells to a pro-inflammatory phenotype.

Despite the acknowledged overlap between chronic pain and obesity, the symptom cluster described above has not been explored in a prospective study designed to promote weight

loss. To address the hypothesis that the spatial distribution of pain, affect, and somatic symptoms would each improve following weight loss, we conducted a prospective study designed to achieve weight reduction in obese individuals using a well-established and successful caloric restriction weight loss intervention.³² We hypothesized that both the spatial distribution of pain and severity of associated somatic symptoms would improve following weight loss. In a subsample of participants, we also measured inflammation-linked cytokines before and after weight loss to determine if inflammatory measures changed following the intervention.

Methods

Recruitment & Participants

The Weight Management Program is a 2-year multidisciplinary, multicomponent intensive behavioral lifestyle program designed for obese participants (to be eligible individuals must have BMI ≥ 30 kg/m², or ≥ 28 kg/m² in Asian Americans). Participants were referred to the program by clinicians in the University of Michigan Health System and by community physicians. The program has been described in detail previously.³² Initially, 241 individuals enrolled in the study and provided baseline data. Of these, 157 completed the weight loss program (65%). Of the 84 who did not complete the program, 42 were lost to follow-up (50%) and 42 (50%) withdrew. Common reasons for withdrawal included change in life circumstances (e.g., moving, pregnancy) socioeconomic factors, and change in insurance coverage. Those who did and did not complete the program were compared using one-way analysis of variance (ANOVA) on key study variables at time of study entry (see Results). Of the 157 individuals who completed the program 124 (79%) reported pain at baseline or following the intervention. One participant gained weight during the intervention and was excluded from further analyses. Therefore 123 participants were included in longitudinal analyses of centralized pain characteristics. The study was approved by the University of Michigan Institutional Review Board.

Intervention

Weight loss was introduced via a very-low calorie diet (800kcal/day) in the form of total liquid meal replacement for a period of approximately 12 weeks to promote approximately 15% weight loss from baseline weight. The rationale for this approach is multifold: liquid meal replacement limits food choices, reduces unreported caloric intake, eliminates the palatability related to chewing food, divorces participants from unhealthy consumptive behaviors, promotes faster absorption of nutrients, and enhances both initial and long-term weight loss. During the program participants were also encouraged to increase their physical activity gradually to a total of 40 minutes per day of low to moderate intensity, such as walking during the first 12 weeks and to 60–90 minutes of moderate to vigorous physical activity on at least 4 days per week, thereafter. Weight and height were assessed at each of the monthly scheduled visits to a physician and/or dietitian for calculation of BMI. Participants who struggle to adhere to the regimen and lose weight are counseled at these visits, and an additional four weeks may be added to the intervention phase to increase the chance of successful weight loss.

Measures

Demographic, Medical Information, and Physical Activity—Basic information including age, sex, and level of education, smoking status (never/ever) were collected by self-report. The presence/absence of a physician diagnosis of sixteen conditions were collected by standardized form and include history of hypertension, dyslipidemia, and macrovascular disease. Physical activity was assessed with a 4-point measure ranging from “no physical activity weekly” (0) to “vigorous physical activity for at least 20 minutes three or more times per week” (3).

The Spatial Distribution of Pain, Somatic Symptoms, and Affect—The American College of Rheumatology (ACR) preliminary diagnostic criteria for fibromyalgia (FM) modified for clinical and epidemiological studies⁴⁴ was used to assess diffuse pain as well as the presence and severity of co-morbid symptoms typically seen in centralized pain states. The ACR modified criteria consists of two scales: the widespread pain index (WPI) contains 19 body sites that can be endorsed as painful (shown in Fig. 1) and Symptom Severity (SS) scale that measures several symptoms considered part of the centralized pain continuum (fatigue, unrefreshing sleep, cognitive difficulties, depressed mood, abdominal pain, headache.) These scales have been validated against other measures of bodily pain and somatic symptoms.⁴⁴ Use of the modified criteria in the general population indicates a dimensional, rather than categorical construct, supporting the use of the ACR score as an indicator of the underlying centralized pain construct.⁴³ This modified score (range 0–31) has subsequently been shown to predict important features of complex chronic pain, including a failure to respond to surgical procedures intended to relieve pain.^{4, 17} The 30-item Inventory of Depressive Symptomology³³ (IDS) self-report was used to measure symptoms of depression.

Inflammatory Data

Fasting blood serum was collected in EDTA tubes and stored at -80°C prior to the intervention and again post weight-loss. Several cytokines were selected that are known to have both pro-inflammatory and regulatory effects: Interleukin (IL)-6, 1 β , 10, tumor necrosis factor (TNF)- α and Interferon- γ were assayed in duplicate using Luminex xMap® technology with a high-sensitivity multiplex panel (MILLIPLEX® HCYTOMAG-60K; inter-assay CV < 20%, intra-assay CV < 5%) and C-Reactive Protein (CRP) by high-sensitivity immunoturbidimetric assay (Sekure Chemistry™ 082; inter and intra-assay CV < 10%) at the Michigan Diabetes Research Center (MDRC) Chemistry Laboratory. The assay range for CRP: .1–80 mg/L; IL-6: .18–750 pg/mL; IL-1 β : .49–2000 pg/mL; IL-10: 1.46–6000 pg/mL; TNF- α : .45–1750 pg/mL; IFN- γ : .61–2500 pg/mL. Samples were limited to a subset of participants who consented to this optional blood draw at both time points (n = 31). These individuals were compared to the rest of the cohort on key study variables by one-way ANOVA (see Results).

Statistical Analyses

Longitudinal analyses—To determine if the symptoms changed following the intervention, the SSI score, total ACR modified criteria score and total IDS score, were

compared by paired-sample t-test, and Wilcoxon signed-rank test for physical activity data, between baseline (pre-weight loss) and again at the end of the weight-loss intervention. Non-parametric tests were used to evaluate physical activity given the limited range and ordinal nature of the scale (0–3). We evaluated the spatial distribution of pain using a mixed effects logistic regression model, with the primary outcome being the probability of endorsing any of the 19 sites as painful and the predictor being the time of evaluation (baseline or post-weight-loss). These models employ random intercepts for both subject and the site on the body map. This model reflects the probability of having pain at any given site while accounting for the variance associated with subject-specific response patterns and specific body sites. This approach is intended to model the propensity towards generalized hyperalgesia – the model accounts for the greater likelihood that an individual will have pain in the lower back, for instance, than the forearm, while also accounting for subject specific response patterns. This model allows for a more accurate estimation of the effect of time (i.e., weight loss or other changes during the intervention) on the overall likelihood of having pain at any site on the body. The appropriateness of including these random effects was confirmed by likelihood testing of nested models. Analyses were conducted in SPSS v. 24 and R.

Secondary Analyses—To consider the effects of sex and magnitude of weight loss on symptom change, we used general linear models in which the outcome was the symptom change score (baseline symptom-post-intervention symptom), with baseline symptom levels, sex, weight loss group, and physical activity group, as primary predictors. Weight loss groups were defined by percentage body weight lost: less than 10% (n=24), and greater than 10% (n=99). Physical activity groups were defined as those who increased physical activity over the course of the intervention (n=63) and those who did not (n=49). Estimated Marginal Means (EMMs) of change scores were compared by group. A similar analytic procedure was used to test sex differences and weight loss magnitude effects on the change in the spatial distribution of pain. Sex by time, weight loss group by time, and physical activity group by time, interaction terms were tested to determine if these variables were associated with significantly different effects of time (baseline versus post-intervention) on the probability of having pain at any site on the body map.

We also conducted correlations between scores for depression, the SSI, the WPI, and the total ACR score, to determine if improvements in each domain were associated with one another.

Cytokine Data—Greater than 98% of the cytokine values were within detectable limits (365/372). The remaining 7 values were below detectable limits and set to 0 for subsequent analyses. Non-parametric paired sample tests were performed on the cytokine values using Wilcoxon ranked tests. In addition to raw cytokine values, the ratio of anti-inflammatory cytokine IL-10 to pro-inflammatory IL-6 and CRP was calculated for each time point and compared by Wilcoxon ranked test as well.

Inflammation and Symptoms—The association between levels of each cytokine and modified ACR score was tested by nonparametric correlation using Spearman's rank procedures. The change in cytokine values that were significantly altered following weight

loss were correlated with symptom change scores using Spearman's rank procedures. We used the Spearman rank procedure because it is less affected by outliers and non-normal data than Pearson correlations.

Results

Baseline Comparison of Study Completers and Non-Completers

At baseline there were no statistically significant differences between the 84 participants who withdrew from the study or were lost to follow-up compared to the 157 completers on the ACR modified total score ($p = .196$), WPI ($p = .904$), IDS score ($p = .788$), number of comorbidities ($p = .139$), or BMI ($p = .282$). The difference in the SS score trended toward significance ($p = .057$) such that non-completers appeared to have slightly higher SS scores (non-completer mean = 4.55, SD = 2.15; completer mean = 3.90, SD = 2.72).

Demographic and medical information

The 123 participants included in the longitudinal analyses were middle-aged (mean 51 years (SD=10.96, range 23–69), 67% were female, and most were educated (81% with a college degree), and employed (85%). See Table 1. The average baseline weight and BMI were 116 kg. (SD=23.27) and 40 kg/m² (SD=6.45) respectively. The average number of comorbid conditions was 3.06 (SD=1.64) and the three most common conditions were dyslipidemia (48%), hypertension (44%), and depression (38%). Additionally, osteoarthritis was reported by 19% of the sample.

Weight loss

On average, participants lost 16.05% of their baseline weight (SD= 6.54%; range = 2%–30% loss). 80% (n=99) lost at least 10% of their body weight. There were no statistically significant differences between men and women on initial BMI (men, mean = 40.54, SD = 6.99; women, mean = 40.28, SD= 6.23; $p = .84$), percent of body weight lost (men, mean = 16.3%, SD = 7.5%; women, mean = 15.95%, SD= 6.08%, $p = .810$), or proportion of individuals who lost 10% or greater body weight (men= 78.05%, women = 81.71%, $p = .63$).

Post intervention changes

The total 2011 modified ACR score declined significantly following weight loss (mean (SD), baseline = 6.42 (4.26), post weight-loss = 5.42 (3.47); $p = .004$) as did the SSI score (baseline = 4.12 (2.87), post weight-loss = 3.49 (2.48); $p = .002$) and the IDS (baseline = 17.40 (9.22), post weight-loss = 11.78 (6.95); $p < .001$). A total of 112 participants reported physical activity levels at both time points. Of these 56% (n=63) increased physical activity (1 point increase on the 4-point scale).

Spatial distribution of pain

The probability of a participant endorsing pain at any given site on the body map declined approximately 20% following weight-loss (Odds Ratio [OR]= .799, 95% Confidence Intervals [CI] = .661, .968; $p = .022$). The areas where change appeared to be greatest were the lower legs, lower back, chest, and jaw. See Figure 1.

Secondary Analyses

Men showed greater reductions in the total ACR FM score (Estimated Marginal Mean [EMM] [SE], men = -1.702 [.486], women = $.102$ [.382], $p = .002$) and SSI (EMM [SE], men = -1.052 [.306], women = $-.099$ [.245], $p = .009$) compared to women. There were no significant differences in IDS change scores (EMM [SE], men = -5.559 [.965], women = -4.309 [.744], $p = .275$) or in pain reduction (sex by time interaction term, $p = .973$).

Losing more than 10% of body weight was associated with greater reductions in the ACR FM score (EMM [S.E.], 10% group = -1.621 [.302], < 10% group = $.022$ [.580], $p = .012$) and the IDS score (EMM [S.E.], 10% group = -6.433 [.595], < 10% group = -3.435 [1.124], $p = .018$) but not with the SSI (EMM [S.E.], 10% group = $-.932$ [.194], < 10% group = $-.219$ [.374], $p = .09$). Similarly, losing more than 10% of body weight was associated with greater a reduction in the spatial distribution of pain post-intervention (time by weight loss group interaction term, $p = .019$). Individuals who lost 10% or more of body weight were approximately 30% less likely to endorse pain at any body site after the intervention (OR = .699, 95% CI = .548, .891) while individuals who lost less than 10% showed no significant change in the likelihood of reporting pain (OR = 1.284, 95% CI = .798, 1.959). The distribution of these changes is shown in Figure 1.

There were no significant effects of change in physical activity on any measure of symptom reduction (all $p > .43$).

The change in the WPI and the SSI were associated ($r = .208$, $p = .021$), and the ACR total score ($r = .221$, $p = .015$) and SSI change ($r = .348$, $p < .001$) were both associated with the change in depression. The change in depression and WPI were not associated ($r = .030$, $p = .74$).

Inflammatory Data

Comparison of the Subsample with Inflammatory Data to the Rest of the Cohort—Individuals who provided blood at both time points for inflammatory analyses did not differ on baseline symptom characteristics, number of comorbid conditions, BMI, or symptom changes (all $p > .19$).

Pre and post-weight loss—Following weight loss, levels of IL-10 increased significantly ($p = .002$) while the other cytokine levels did not significantly change (all $p > .05$). See Table 2 and Figure 2. The ratio of IL-10 to IL-6 and CRP also increased significantly following weight loss (both $p < .05$), suggesting an increase in anti-inflammatory tone after caloric restriction. The increase in IL-10 remained statistically significant after correction for multiple comparisons ($p < .05$).

Relationship Between Cytokines and Symptoms—At baseline, higher levels of IL-6 were associated with higher modified ACR total scores (Spearman $r = .424$, $p = .017$), and post weight loss, both higher levels of IL-6 (Spearman $r = .360$, $p = .047$) and IL-1 β (Spearman $r = .362$, $p = .046$) were associated with higher modified ACR total scores. Other cytokines were not associated with modified ACR scores (all $p > .05$). See Table 3. At baseline, BMI was not related to levels of any cytokine (all $p > .05$) while post weight loss,

higher levels of CRP were related to greater BMI (Spearman $r = .431$, $p = .016$). Levels of physical activity were unrelated to cytokine values at either time point (all $p > .05$).

The change in IL-10 was not significantly associated with the change in the WPI ($p = .23$), SS score ($p = .385$), total ACR modified score ($p = .13$), depression score ($p = .89$) or the percentage of weight lost ($p = .11$).

Discussion

This study's chief finding is that following weight loss induced by a low calorie diet the spatial distribution of pain and somatic symptoms improved, two hallmarks of complex chronic pain conditions. These results appear to be the serendipitous result of weight loss, as the participants were not seeking treatment for pain/somatic symptoms. After the intervention fewer individuals had pain in weight bearing areas like the lower back and lower leg as has been noted in many previous studies,^{25, 26} but there was also some improvement in non-weight bearing regions like the jaw, chest and abdomen. These patterns were not consistent with a simple global reduction in pain, but seemed to vary by site as there was some pattern of worsening in the upper back, neck, and shoulders. In addition to the composite measure of symptom severity (i.e., fatigue, sleep difficulties) depression scores improved substantially. Those who lost more than 10% of their initial body weight showed greater improvement in depression, pain, and total modified ACR scores. Over four-tenths of those who lost greater than 10% of their body weight showed at least a 30% reduction in ACR scores, a metric that, when applied to other pain measures, corresponds well with patients ratings of "much improved."³⁷ Finally, men appeared to improve more in somatic symptoms and on the total ACR score than women after the intervention. Though physical activity increased from baseline to post-intervention, this change was not associated with the change in symptoms. Those who completed the study were not substantially different from those lost to follow-up/withdrawal, which suggests that selection effects do not play a large part in our results.

Our analytic approach was designed to assess a general vulnerability to bodily pain. In the current study, examining specific regions of improvement and worsening between those who did and did not lose 10% of body weight suggests the greatest improvement in the lower back and other weight-bearing areas, with some improvement in the jaw, chest, and abdomen. This finding coupled with the association between improvements in pain and somatic symptoms, is consistent with some component of the observed changes involving a global neurobiological or psychological mechanism, though it is also possible that improvements in pain governed by local mechanisms ultimately lead to improvements in energy, sleep and affect. A previous study using resting-state functional connectivity found that obese individuals show increased connectivity to the salience network from several regions including the amygdala and insula,¹⁴ a pattern of connectivity which has been linked to an increased likelihood of finding experimental stimuli painful.⁴² It is possible then that weight loss may alter such patterns of connectivity in a manner that is beneficial for the perception of pain. Improved sleep quality is a well-established correlate of weight loss in obese individuals with apnea,¹ but sleep quality is also reduced in obese individuals without apnea.³⁹ Improved sleep may therefore play a role in improved pain, somatic symptoms, and

affect.⁴⁰ Depression improved substantially and are consistent with improved affect, self-efficacy, and self-esteem noted in other weight loss studies.¹²

Improvements in mood may be an important component of improvement in somatic symptoms, but do not appear to be associated with improvements in pain in our study. This may be because we measured the spatial distribution of pain, rather than intensity, as it is the latter outcome which has been shown to improve significantly with improving mood.³⁴ It was somewhat surprising that changes in physical activity were not associated with greater changes in symptoms, as this has been suggested specifically as a means to improve chronic pain in obesity.²⁹ It may be that calorie restriction at this level is not conducive to moderate or major increases in physical activity that would show stronger relationships with symptom change. We suspect that the improvements noted in this study are the result of dynamic and complementary factors that will require more assessments to characterize the relevant causal pathways.

The change in symptoms is particularly noteworthy because they were detectable in a sample of individuals with relatively low levels of baseline symptoms (i.e., an average of two painful body sites), who were not seeking treatment for pain, mood, or somatic symptoms. This suggests that pain and somatic symptoms do not need to be at “pathological” or severe levels to improve following weight loss. This raises the important question of whether individuals with chronic pain would demonstrate similar levels of improvement relative to their baseline symptoms as the participants in this study. The greater improvement demonstrated by men on the SSI and ACR score is important, as women disproportionately suffer from conditions characterized by the somatic symptoms measured in the SSI (i.e. chronic fatigue syndrome)³⁸ and these results would suggest that weight loss is more beneficial for pain and affect symptom domains. A recent meta-analysis found that men who lose weight experience a substantial rebound in total and free testosterone,⁸ which have been associated specifically with self-reported physical vigor/wellbeing.⁴⁵

The anti-inflammatory cytokine IL-10 appeared to be greatly increased following the intervention, and this remained true when levels of IL-10 were compared to concurrent levels of inflammation-promoting cytokines. These increases however were not associated with the magnitude of change in symptoms. An increase in IL-10 was previously found following weight loss in an exercise/caloric restriction intervention in 78 obese individuals¹⁹ and studies have indicated that levels of IL-10 and the IL-10 response to immune provocation are reduced in individuals with metabolic syndrome,¹³ In vitro studies show that IL-10 inhibits NF- κ B activity in adipocytes, reducing pro-inflammatory signaling²³ and animal models show that IL-10 protects adipocytes from macrophages with a pro-inflammatory phenotype;²⁴ this may explain why the number of adipose tissue infiltrating macrophages is reduced following bariatric surgery.⁵ These findings suggest that IL-10 reduces inflammatory tone in adipose tissue and may be helpful in reducing inflammation in/near vulnerable joints. At the same time, IL-10 treatment has been shown to improve centrally-induced hyperalgesia in animal models.³¹ A recent study has demonstrated convincingly that IL-10 reduces the number of voltage-gated sodium channels in the dorsal root ganglion of animals after peripheral nerve injury and attenuates mechanical nerve injury.³⁵ Therefore there are plausible pathways by which IL-10 activity could limit both

peripherally and centrally mediated sensitivity to pain. Determining through additional assessments of inflammatory activity if shifts in inflammatory tone precede symptom improvement or simply parallel them are needed.

Limitations

Our inflammatory analyses were limited to a subsample of participants. The analyses relied on two time points, making true longitudinal inferences difficult to determine. The measure of pain we used only considers the distribution, rather than the intensity of reported pain. The lack of an objective measure of physical activity is likewise a limitation. Similarly, without a control group it is not possible to calculate possible regression-to-the-mean type effects.

Conclusions and Future Directions

These analyses suggest that caloric restriction and weight loss positively impact several symptom domains that commonly affect chronic pain populations. It is therefore plausible that similar interventions could positively impact pain, affect, and somatic symptoms in clinical populations. In addition to measures of complex chronic pain and related measures of clinical pain, future studies using quantitative sensory testing techniques may provide important mechanistic information about hyperalgesia in obesity. Sex-differences in the effects of weight-loss on different symptom domains should be replicated and expanded. A better understanding of the mechanisms behind these effects, including any role for inflammatory processes, may be gleaned from longitudinal studies with more assessments.

Acknowledgments

This project was supported in part by Grant Number P30DK020572 (MDRC) from the National Institute of Diabetes and Digestive and Kidney Diseases, Grant Number K12 DE023574 from the National Institute of Dental and Craniofacial Research. Dr. Harte has received research funding from Aptinyx, Cerephex, Forest Laboratories, Eli Lilly and Merck; and served as a consultant for Pfizer, Analgesic Solutions, Aptinyx, and deCode Genetics. Dr. Williams is currently the President of the American Pain Society; he has served as a consultant with Pfizer Inc. and with Community Health Focus Inc. Dr. Clauw has received research funding from Cerephex, Forest, Merck, and Pfizer, and serves as a consultant for Tonix, Theravance, Cerephex, Pfizer, Abbott, Merck, Eli Lilly, UCB, Johnson & Johnson, Forest Laboratories, and Purdue Pharma.

References

1. Ashrafian H, Toma T, Rowland SP, Harling L, Tan A, Efthimiou E, Darzi A, Athanasiou T. Bariatric surgery or non-surgical weight loss for obstructive sleep apnoea? A systematic review and comparison of meta-analyses. *Obesity surgery*. 2015; 25:1239–1250. [PubMed: 25537297]
2. Bixler E, Vgontzas A, Lin H-M, Calhoun S, Vela-Bueno A, Kales A. Excessive daytime sleepiness in a general population sample: the role of sleep apnea, age, obesity, diabetes, and depression. *The Journal of Clinical Endocrinology & Metabolism*. 2005; 90:4510–4515. [PubMed: 15941867]
3. Brummett CM, Janda AM, Schueller CM, Tsodikov A, Morris M, Williams DA, Clauw DJ. Survey Criteria for Fibromyalgia Independently Predict Increased Postoperative Opioid Consumption after Lower-extremity Joint Arthroplasty A Prospective, Observational Cohort Study. *The Journal of the American Society of Anesthesiologists*. 2013; 119:1434–1443.
4. Brummett CM, Janda AM, Schueller CM, Tsodikov A, Morris M, Williams DA, Clauw DJ. Survey Criteria for Fibromyalgia Independently Predict Increased Postoperative Opioid Consumption after Lower Extremity Joint Arthroplasty: A Prospective, Observational Cohort Study. *Anesthesiology*. 2013; 119

5. Canello R, Henegar C, Viguerie N, Taleb S, Poitou C, Rouault C, Coupaye M, Pelloux V, Hugol D, Bouilliot JL, Bouloumie A, Barbatelli G, Cinti S, Svensson PA, Barsh GS, Zucker JD, Basdevant A, Langin D, Clement K. Reduction of macrophage infiltration and chemoattractant gene expression changes in white adipose tissue of morbidly obese subjects after surgery-induced weight loss. *Diabetes*. 2005; 54:2277–2286. [PubMed: 16046292]
6. Choi J, Joseph L, Pilote L. Obesity and C-reactive protein in various populations: a systematic review and meta-analysis. *Obesity Reviews*. 2013; 14:232–244. [PubMed: 23171381]
7. Clauw DJ. Fibromyalgia: a clinical review. *Jama*. 2014; 311:1547–1555. [PubMed: 24737367]
8. Corona G, Rastrelli G, Monami M, Saad F, Luconi M, Lucchese M, Facchiano E, Sforza A, Forti G, Mannucci E. Body weight loss reverts obesity-associated hypogonadotropic hypogonadism: a systematic review and meta-analysis. *European Journal of Endocrinology*. 2013; 168:829–843. [PubMed: 23482592]
9. Dantzer R, Kelley KW. Twenty years of research on cytokine-induced sickness behavior. *Brain, behavior, and immunity*. 2007; 21:153–160.
10. Davis LL, Kroenke K, Monahan P, Kean J, Stump TE. The SPADE Symptom Cluster in Primary Care Patients With Chronic Pain. *Clin J Pain*. 2016; 32:388–393. [PubMed: 26295379]
11. de Heredia FP, Gómez-Martínez S, Marcos A. Obesity, inflammation and the immune system. *Proceedings of the Nutrition Society*. 2012; 71:332–338. [PubMed: 22429824]
12. Dixon JB, Dixon ME, O'Brien PE. Depression in association with severe obesity: changes with weight loss. *Archives of internal medicine*. 2003; 163:2058–2065. [PubMed: 14504119]
13. Esposito K, Pontillo A, Giugliano F, Giugliano G, Marfella R, Nicoletti G, Giugliano D. Association of low interleukin-10 levels with the metabolic syndrome in obese women. *The Journal of Clinical Endocrinology & Metabolism*. 2003; 88:1055–1058. [PubMed: 12629085]
14. García-García I, Jurado MÁ, Garolera M, Segura B, Sala-Llonch R, Marqués-Iturria I, Pueyo R, Sender-Palacios MJ, Vernet-Vernet M, Narberhaus A. Alterations of the salience network in obesity: a resting-state fMRI study. *Human brain mapping*. 2013; 34:2786–2797. [PubMed: 22522963]
15. Häuser W, Bernardy K, Üçeyler N, Sommer C. Treatment of fibromyalgia syndrome with antidepressants: a meta-analysis. *Jama*. 2009; 301:198–209. [PubMed: 19141768]
16. Illi J, Miaskowski C, Cooper B, Levine JD, Dunn L, West C, Dodd M, Dhruva A, Paul SM, Baggett C, Cataldo J, Langford D, Schmidt B, Aouizerat BE. Association between pro- and anti-inflammatory cytokine genes and a symptom cluster of pain, fatigue, sleep disturbance, and depression. *Cytokine*. 2012; 58:437–447. [PubMed: 22450224]
17. Janda AM, As-Sanie S, Rajala B, Tsodikov A, Moser SE, Clauw DJ, Brummett CM. Fibromyalgia survey criteria are associated with increased postoperative opioid consumption in women undergoing hysterectomy. *The Journal of the American Society of Anesthesiologists*. 2015; 122:1103–1111.
18. Jia H, Lubetkin EI. The impact of obesity on health-related quality-of-life in the general adult US population. *Journal of public health*. 2005; 27:156–164. [PubMed: 15820993]
19. Jung SH, Park HS, Kim KS, Choi WH, Ahn CW, Kim BT, Kim SM, Lee SY, Ahn SM, Kim YK, Kim HJ, Kim DJ, Lee KW. Effect of weight loss on some serum cytokines in human obesity: increase in IL-10 after weight loss. *The Journal of nutritional biochemistry*. 2008; 19:371–375. [PubMed: 17614271]
20. Kennedy J, Roll JM, Schraudner T, Murphy S, McPherson S. Prevalence of persistent pain in the US adult population: new data from the 2010 national health interview survey. *The Journal of Pain*. 2014; 15:979–984. [PubMed: 25267013]
21. King WC, Chen J-Y, Belle SH, Courcoulas AP, Dakin GF, Elder KA, Flum DR, Hinojosa MW, Mitchell JE, Pories WJ. Change in pain and physical function following bariatric surgery for severe obesity. *Jama*. 2016; 315:1362–1371. [PubMed: 27046364]
22. Lee YH, Choi SJ, Ji JD, Song GG. Candidate gene studies of fibromyalgia: a systematic review and meta-analysis. *Rheumatology international*. 2012; 32:417–426. [PubMed: 21120487]
23. Lira FS, Rosa JC, Pimentel GD, Seelaender M, Damaso AR, Oyama LM, do Nascimento CO. Both adiponectin and interleukin-10 inhibit LPS-induced activation of the NF- κ B pathway in 3T3-L1 adipocytes. *Cytokine*. 2012; 57:98–106. [PubMed: 22047972]

24. Lumeng CN, Bodzin JL, Saltiel AR. Obesity induces a phenotypic switch in adipose tissue macrophage polarization. *The Journal of clinical investigation*. 2007; 117:175–184. [PubMed: 17200717]
25. Messier SP, Mihalko SL, Legault C, Miller GD, Nicklas BJ, DeVita P, Beavers DP, Hunter DJ, Lyles MF, Eckstein F. Effects of intensive diet and exercise on knee joint loads, inflammation, and clinical outcomes among overweight and obese adults with knee osteoarthritis: the IDEA randomized clinical trial. *Jama*. 2013; 310:1263–1273. [PubMed: 24065013]
26. Miller GD, Nicklas BJ, Loeser RF. Inflammatory biomarkers and physical function in older, obese adults with knee pain and self-reported osteoarthritis after intensive weight-loss therapy. *Journal of the American Geriatrics Society*. 2008; 56:644–651. [PubMed: 18312558]
27. Ogden CL, Carroll MD, Kit BK, Flegal KM. Prevalence of childhood and adult obesity in the United States, 2011–2012. *Jama*. 2014; 311:806–814. [PubMed: 24570244]
28. Okifuji A, Donaldson GW, Barck L, Fine PG. Relationship between fibromyalgia and obesity in pain, function, mood, and sleep. *The Journal of Pain*. 2010; 11:1329–1337. [PubMed: 20542742]
29. Paley CA, Johnson MI. Physical Activity to Reduce Systemic Inflammation Associated With Chronic Pain and Obesity: A Narrative Review. *Clin J Pain*. 2016; 32:365–370. [PubMed: 25988939]
30. Phillips K, Clauw DJ. Review: Central pain mechanisms in the rheumatic diseases: Future directions. *Arthritis & Rheumatism*. 2013; 65:291–302. [PubMed: 23045168]
31. Plunkett JA, Yu CG, Easton JM, Bethea JR, Yezierski RP. Effects of interleukin-10 (IL-10) on pain behavior and gene expression following excitotoxic spinal cord injury in the rat. *Experimental neurology*. 2001; 168:144–154. [PubMed: 11170729]
32. Rothberg AE, McEwen LN, Fraser T, Burant CF, Herman WH. The impact of a managed care obesity intervention on clinical outcomes and costs: A prospective observational study. *Obesity*. 2013; 21:2157–2162. [PubMed: 24136667]
33. Rush AJ, Gullion CM, Basco MR, Jarrett RB, Trivedi MH. The Inventory of Depressive Symptomatology (IDS): psychometric properties. *Psychol Med*. 1996; 26:477–486. [PubMed: 8733206]
34. Scott EL, Kroenke K, Wu J, Yu Z. Beneficial Effects of Improvement in Depression, Pain Catastrophizing, and Anxiety on Pain Outcomes: A 12-Month Longitudinal Analysis. *The journal of pain : official journal of the American Pain Society*. 2016; 17:215–222. [PubMed: 26542153]
35. Shen KF, Zhu HQ, Wei XH, Wang J, Li YY, Pang RP, Liu XG. Interleukin-10 down-regulates voltage gated sodium channels in rat dorsal root ganglion neurons. *Experimental neurology*. 2013; 247:466–475. [PubMed: 23357618]
36. Shiri R, Karppinen J, Leino-Arjas P, Solovieva S, Viikari-Juntura E. The association between obesity and low back pain: a meta-analysis. *American journal of epidemiology*. 2010; 171:135–154. [PubMed: 20007994]
37. ten Klooster PM, Drossaers-Bakker KW, Taal E, van de Laar MAFJ. Patient-perceived satisfactory improvement (PPSI): Interpreting meaningful change in pain from the patient's perspective. *Pain*. 2006; 121:151–157. [PubMed: 16472915]
38. van't Leven M, Zielhuis GA, van der Meer JW, Verbeek AL, Bleijenberg G. Fatigue and chronic fatigue syndrome-like complaints in the general population. *European journal of public health*. 2009; 20:251–257. [PubMed: 19689970]
39. Vgontzas AN, Tan TL, Bixler EO, Martin LF, Shubert D, Kales A. Sleep apnea and sleep disruption in obese patients. *Archives of internal medicine*. 1994; 154:1705–1711. [PubMed: 8042887]
40. Vitiello MV, Rybarczyk B, Von Korff M, Stepanski EJ. Cognitive behavioral therapy for insomnia improves sleep and decreases pain in older adults with co-morbid insomnia and osteoarthritis. *J Clin Sleep Med*. 2009; 5:355–362. [PubMed: 19968014]
41. Weisberg SP, McCann D, Desai M, Rosenbaum M, Leibel RL, Ferrante AW Jr. Obesity is associated with macrophage accumulation in adipose tissue. *The Journal of clinical investigation*. 2003; 112:1796–1808. [PubMed: 14679176]

42. Wiech K, Lin C-s, Brodersen KH, Bingel U, Ploner M, Tracey I. Anterior insula integrates information about salience into perceptual decisions about pain. *Journal of Neuroscience*. 2010; 30:16324–16331. [PubMed: 21123578]
43. Wolfe F, Brähler E, Hinz A, Häuser W. Fibromyalgia prevalence, somatic symptom reporting, and the dimensionality of polysymptomatic distress: results from a survey of the general population. *Arthritis care & research*. 2013; 65:777–785. [PubMed: 23424058]
44. Wolfe F, Clauw DJ, Fitzcharles MA, Goldenberg DL, Hauser W, Katz RS, Mease P, Russell AS, Russell IJ, Winfield JB. Fibromyalgia criteria and severity scales for clinical and epidemiological studies: a modification of the ACR Preliminary Diagnostic Criteria for Fibromyalgia. *The Journal of rheumatology*. 2011; 38:1113–1122. [PubMed: 21285161]
45. Wu FC, Tajar A, Beynon JM, Pye SR, Silman AJ, Finn JD, O'Neill TW, Bartfai G, Casanueva FF, Forti G. Identification of late-onset hypogonadism in middle-aged and elderly men. *New England Journal of Medicine*. 2010; 363:123–135. [PubMed: 20554979]

Highlights

- Obese patients with pain underwent a calorie-restriction weight loss intervention
- The spatial distribution of pain, fatigue, and depressive symptoms improved
- Improvement was greatest in those losing 10% or more of their body weight
- The anti-inflammatory cytokine interleukin-10 increased after weight loss

Perspective

This article presents the impact of a weight loss intervention on characteristics of chronic pain, including the spatial distribution of pain and comorbid somatic symptoms. Weight loss appeared to produce larger improvements in somatic symptoms for men.

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

Figure 1.

Illustration of change in pain following weight loss in individuals who lost $\geq 10\%$ and less $< 10\%$ of body weight. Left panel: the 19 areas for selecting pain on the body map. Central and Right panels: the largest circles are body areas where 20% or more of individuals endorsed pain at baseline; medium circles are areas where 10–19% of individuals endorsed pain at baseline; small circles are areas where $< 10\%$ of individuals endorsed pain at baseline. Blue represents areas where the proportion of individuals endorsing pain following weight loss decreased (i.e., improvement), whereas red represents areas where the proportion increased (i.e. worsening). Color intensity corresponds to the magnitude of change.

Figure 2.
Interleukin-10 values at baseline and following weight-loss for all 31 participants with inflammatory data.

Table 1

Participant characteristics.

Characteristic Mean, range, (SD)	n=123
ACR total score	6.42, 0–20 (4.26)
Widespread Pain Index	2.30, 0–11 (2.24)
Symptom Severity Score	4.12 0–11 (2.24)
IDS Score	17.40 3–48 (9.23)
Number of Chronic Conditions	3.05 0–9 (1.62)
Age	50.77 23–69 (10.96)
Body Mass Index	40.34 30–60 (6.46)
Weight (kg)	115.83 73–195 (23.28)
Physical Activity	%
no physical activity weekly	9
only light physical activity in most weeks	52
vigorous physical activity for at least 20 minutes once or twice a week	23
Vigorous physical activity for at least 20 minutes three or more times per week	14
Female	67
Smoker	
(current/	4
Former	29
never)	67
College Degree	81
Employed	85

Table 2

Inflammatory values before and after weight-loss (n=31).

Cytokine Median Interquartile Range	Baseline	Post Intervention	Wilcoxon Signed Ranks p
Interferon- γ	6.00 2.90–14.20	6.00 3.10–15.70	.150
Tumor Necrosis Factor- α	5.90 4.60–7.00	5.50 4.70–6.90	.657
Interleukin-1 β	.90 .70–1.40	1.00 .70–1.60	.863
Interleukin-6	3.10 1.90–4.10	3.00 2.40–6.30	.081
Interleukin-10	17.10 3.80–26.00	22.00 7.70–40.70	.002
C-Reactive Protein	4.50 2.70–8.50	4.10 1.50–8.10	.222
Interleukin-10/Interleukin-6 ratio	5.17 1.81–8.19	5.95 3.61–8.29	.010
Interleukin-10/C-Reactive Protein ratio	2.55 1.43–5.91	6.33 1.63–13.30	<.001

Table 3

Association between levels of inflammation-linked cytokines and ACR total score before and after weight loss.

Cytokine	Baseline		Post - Intervention	
	Spearman Correlation	p	Spearman Correlation	p
Interferon- γ	.238	.197	.218	.239
Tumor Necrosis Factor- α	.088	.638	.232	.209
Interleukin-1 β	.220	.234	.362	.046
Interleukin-6	.424	.017	.360	.047
Interleukin-10	.263	.153	.201	.278
C-Reactive Protein	.212	.235	.345	.057